companydata.dkcompanydata.dk

ZEALAND PHARMA A/S: Financial statements 2019

CVR: 20045078

Source: annual report 2019, Danish Business Authority

01/01/2019 – 31/12/2019

ZEALAND PHARMA A/S (CVR 20045078) has filed annual accounts for 2019. In 2019, the company reported revenue of DKK 41,333,000 and a net result of DKK -571,541,000 compared with DKK 581,282,000 the year before. That is an increase of 8.8% compared with the year before. The profit margin was -1,382.8%. Equity in the 2019 report amounted to DKK 1,242,673,000. The solvency ratio was 77.7%.

Revenue
DKK 41,333,000
Profit/Loss
DKK -571,541,000
Equity
DKK 1,242,673,000
Total Assets
DKK 1,599,514,000

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
201941.3M--571.5M1.2B-
201838M-581.3M1.1B-
2017139.8M--272.3M528.5M-
2016234.8M--153.9M278.2M-
2015187.7M165.4M-114M252.2M-

Official annual report

View the official annual report directly on the page with a Pro subscription.

Screen every Danish company

Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.

Try company screening

Events in 2019

Matthew Donald Dallas joins ZEALAND PHARMA A/S as directorOct 25, 2019

As of October 25, 2019, Matthew Donald Dallas is registered as director of ZEALAND PHARMA A/S.

ZEALAND PHARMA A/S: The 2018 annual report is outApr 29, 2019

ZEALAND PHARMA A/S has published its annual report for 2018. Revenue came to DKK 37,977,000, and the net result was DKK 581,282,000.

Adam Sinding Steensberg joins ZEALAND PHARMA A/S as directorApr 22, 2019

As of April 22, 2019, Adam Sinding Steensberg is registered as director of ZEALAND PHARMA A/S.

Emmanuel Dulac joins ZEALAND PHARMA A/S as adm. dir.Apr 22, 2019

As of April 22, 2019, Emmanuel Dulac is registered as adm. dir. of ZEALAND PHARMA A/S.

Emmanuel Dulac joins ZEALAND PHARMA A/S as adm. dir.Apr 22, 2019

As of April 22, 2019, Emmanuel Dulac is registered as adm. dir. of ZEALAND PHARMA A/S.

Emmanuel Dulac steps down as adm. dir. of ZEALAND PHARMA A/SApr 22, 2019

As of April 22, 2019, Emmanuel Dulac has stepped down as adm. dir. of ZEALAND PHARMA A/S.

Adam Sinding Steensberg steps down as adm. dir. of ZEALAND PHARMA A/SApr 21, 2019

As of April 21, 2019, Adam Sinding Steensberg has stepped down as adm. dir. of ZEALAND PHARMA A/S.

Kirsten Aarup Drejer joins the board of ZEALAND PHARMA A/SApr 4, 2019

As of April 4, 2019, Kirsten Aarup Drejer has joined the board of directors of ZEALAND PHARMA A/S.

Jeffrey Berkowitz joins the board of ZEALAND PHARMA A/SApr 4, 2019

As of April 4, 2019, Jeffrey Berkowitz has joined the board of directors of ZEALAND PHARMA A/S.

Leonard Kruimer joins the board of ZEALAND PHARMA A/SApr 4, 2019

As of April 4, 2019, Leonard Kruimer has joined the board of directors of ZEALAND PHARMA A/S.

About ZEALAND PHARMA A/S

ZEALAND PHARMA A/S is a Danish company of the type Aktieselskab based in Søborg, founded in 1997. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named ZEALAND PHARMACEUTICALS A/S and PEPTIDE PROBE TECHNOLOGIES ApS. The management consists of Adam Sinding Steensberg and Henriette Wennicke. The board consists of Alf Gunnar Martin Nicklasson (chair), Kirsten Aarup Drejer, Adam Krisko Nygaard and Anneline Nansen. The company's owners include ZEALAND PHARMA A/S, Van Herk Investments B.V. and Van Herk Management Services B.V.. The company has 575 employees (2026). In 2025, the company reported revenue of DKK 9,214,860,000 and a net result of DKK 6,455,008,000 compared with DKK -1,078,828,000 the year before. Equity in the 2025 report amounted to DKK 14,830,613,000.

Source: annual report 2025, Danish Business Authority